Advertisement


Keith McCrae, MD, on Managing Heparin-Induced Thrombocytopenia

2014 ASH Annual Meeting

Advertisement

Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 4848, “Implementation of a Heparin-Induced Thrombocytopenia Management Program Reduces the Cost of Diagnostic Testing and Pharmacologic Treatment in an Academic Medical Center,” presented by Caroline Dupre Vaughn, RN.



Related Videos

Lymphoma

Laurie Sehn, MD, on Radiotherapy in Limited-Stage Diffuse Large B-Cell Lymphoma

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 393, “R-CHOP With or Without Radiotherapy...

Leukemia

Hagop Kantarjian, MD, on Blinatumomab in Precursor B-Cell ALL

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 379,

Myelodysplastic Syndromes
Leukemia

Alan F. List, MD, on Sotatercept in Lower-Risk Myelodysplastic Syndromes

Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 3251, “An Open-Labe...

Leukemia

Richard M. Stone, MD, on the UK NCRI AML17 Trial

Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 7,

Leukemia
Lymphoma

Julie M. Vose, MD, MBA, FASCO, on Ublituximab Plus TGR-1202 in Lymphoma

Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 801, “Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibod...

Advertisement

Advertisement



Advertisement